Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylene Blue MMX for improved adenoma detection during screening or surveillance colonoscopy
NL-OMON41630Phase 3Active, not recruiting
- Sponsor
- Cosmo Pharmaceuticals
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lumeblue in colorectal cancer (CRC) (3 arms), sponsored by Cosmo Pharmaceuticals. Primary endpoint: Primary efficacy endpoint. Started Jun 2014; status: active, not recruiting.
02
Drugs
lumeblue
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON41630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41630.